Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business. Australia-based CSL, which runs a network of ...
Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
Greg Boss, general counsel at Australia-headquartered CSL, says the role of GC has changed to more of a business adviser. Here, he shares his insights into overseeing a legal team at a global company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback